Evaluation and Differential Diagnosis
This patient requires immediate evaluation for MYH9-related disorder (MYH9-RD), which is the most likely diagnosis given the constellation of mild thrombocytopenia with giant platelets, microcytosis, and impaired renal function in a young Black male. 1
Primary Diagnostic Considerations
MYH9-Related Disorder (Most Likely)
The clinical picture strongly suggests MYH9-RD based on:
- Giant platelets (1+) on peripheral smear
- Mild thrombocytopenia (platelet count 134,000/μL)
- Elevated creatinine (1.4 mg/dL) indicating renal impairment
- Young age at presentation
Critical next step: Examine the peripheral blood smear for leukocyte inclusions (Döhle-like bodies), which are pathognomonic for MYH9-RD 1. If present, proceed directly to genetic testing for MYH9 mutations (specifically look for c.2105G>A [p.Arg702His] and related pathogenic variants).
Additional history required:
- Hearing loss (especially early-onset sensorineural)
- Family history of thrombocytopenia, renal disease, or hearing impairment
- History of cataracts
- Prior misdiagnosis as ITP with failed treatments 1
Iron Deficiency Anemia (Concurrent Finding)
The microcytosis (MCV 74.1 fL) and low MCH (25.2 pg/dL) indicate iron deficiency 2, 3:
- Order: Serum ferritin, transferrin saturation (TSAT), iron, and TIBC
- In the absence of inflammation, ferritin <30 μg/L confirms iron deficiency 2
- Important: MCH may be more reliable than MCV for detecting iron deficiency 2
- Consider hemoglobin electrophoresis to exclude thalassemia trait, particularly given the patient's ethnicity and disproportionate microcytosis 2
Renal Dysfunction Evaluation
Creatinine 1.4 mg/dL requires assessment of:
- Estimated GFR calculation
- Urinalysis for proteinuria (nephrotic-range proteinuria is common in MYH9-RD) 1
- Urine protein-to-creatinine ratio
- Blood pressure measurement (hypertension frequently accompanies MYH9-RD renal disease) 1
Secondary Differential Diagnoses to Exclude
Thrombotic Microangiopathy (TMA)
While less likely given normal hemoglobin and hematocrit, evaluate for:
- Peripheral smear: Schistocytes (critical for TMA diagnosis) 4, 5
- LDH, haptoglobin, indirect bilirubin (hemolysis markers)
- Reticulocyte count
- ADAMTS13 activity level if TMA suspected 4, 5
Key distinction: TMA typically presents with microangiopathic hemolytic anemia (MAHA), which this patient does not have given normal Hgb/Hct 5, 6.
Immune Thrombocytopenia (ITP)
Less likely but consider:
- ITP typically does NOT present with giant platelets as a primary feature 7
- No splenomegaly on exam (splenomegaly argues against ITP) 7
- Critical pitfall: MYH9-RD is frequently misdiagnosed as ITP, leading to futile splenectomy and toxic immunosuppression 1
Diagnostic Algorithm
Step 1: Immediate peripheral smear review
- Confirm giant platelets
- Search for leukocyte inclusions (MYH9-RD)
- Count schistocytes (exclude TMA)
- Assess RBC morphology
Step 2: Iron studies
- Ferritin, TSAT, iron, TIBC
- If ferritin <30 μg/L with normal TSAT: absolute iron deficiency 2
- If microcytosis persists with normal iron studies: hemoglobin electrophoresis 2
Step 3: Renal workup
- Urinalysis with microscopy
- Urine protein quantification
- Blood pressure
- Consider renal ultrasound
Step 4: Genetic testing
- If leukocyte inclusions present OR clinical triad of thrombocytopenia + giant platelets + renal dysfunction: MYH9 genetic testing 1
Step 5: Audiometry
- Formal hearing assessment if MYH9-RD suspected 1
Critical Management Points
Do NOT:
- Initiate ITP treatment (steroids, IVIG, splenectomy) without excluding MYH9-RD 1
- Perform platelet transfusions unless active bleeding or urgent surgery (platelet count >130,000/μL is adequate for hemostasis)
- Delay genetic testing if clinical suspicion is high
Do:
- Treat iron deficiency once confirmed (oral iron supplementation, monitor response) 2
- Monitor renal function longitudinally (MYH9-RD causes progressive nephropathy) 1
- Provide genetic counseling if MYH9-RD confirmed (autosomal dominant inheritance)
- Screen for hearing loss and cataracts 1
The combination of giant platelets, mild thrombocytopenia, and renal impairment in a young patient creates a highly specific clinical signature for MYH9-RD that should not be missed, as misdiagnosis leads to inappropriate and potentially harmful interventions 1.